about
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsNewly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness.Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesisActivation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancerA short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Patient-derived tumour xenografts as models for breast cancer drug development.Clinical value of R-spondins in triple-negative and metaplastic breast cancers.The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancerCytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer.AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.Patient-derived xenograft (PDX) models in basic and translational breast cancer research.Interrogating open issues in cancer precision medicine with patient-derived xenografts.Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts.Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers.Interrogating open issues in cancer medicine with patient-derived xenografts.Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG OverexpressionProtein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenograftsThe iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancersBRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancersExpression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination TherapyInhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibitionImproving breast cancer sensitivity to paclitaxel by increasing aneuploidyThe arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancerReprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast CancerA large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancerPARP Inhibition Increases the Response to Chemotherapy in Uveal MelanomaHigh-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancerOestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer
P50
Q27853297-92011FE6-D4E8-4031-A064-E44DF11F0CF2Q28598343-422A61EE-814F-41EF-9B2B-7C6F6BE82A49Q30489256-832E7E16-AC2E-40FE-BDA9-CFF5EAEB4911Q35663687-DDAC210A-4DB4-4BAC-8EE5-D4308988E038Q36424889-3F2B9281-DA8A-467B-8EEF-C69B96137326Q36750699-3CC6DC3E-1E12-40BB-8B1B-3702DCAE01FEQ36889620-C103460A-CBF5-4A28-A0C0-B0DE53D43365Q37565435-31A31286-B695-43F2-8C89-AA7F66205A48Q37605221-687ED766-F62B-434B-9766-8E6B8417D275Q37685449-7516A57C-0788-41A0-B3FD-238410C025D8Q37709099-AC479A35-D319-4E9C-B07F-7D9689148443Q38246052-908B96EB-56FE-480E-B4A7-7B9DDC9E97ADQ38704826-B50D1E5D-9E62-4373-B1C4-632610F880D8Q38726672-4FC9E71C-C2D6-4E7C-A7AE-1D2275701E48Q38747834-D08CDC4A-7EDF-434C-874B-2C3BE3698EE6Q38859608-8949B58F-DDA1-4CCB-A0FE-3BF6B26FE38CQ39057246-DCD721F5-5FF2-41BF-BE12-E4F481D5E072Q39095733-26EB6B56-881A-4F1E-869A-4B278B63C9CFQ40665907-2BDE687D-138D-4E9F-AA91-121EE0E38B71Q42912904-0581821A-6EE4-48AD-819A-BC47EB06C73CQ48131466-75A30120-404F-4E31-874A-14005DFC6A99Q49791843-A3CF272B-349F-4CC2-B945-57ED4DC46414Q50080940-2787258B-89E7-416E-98A4-02D363FC4F94Q53040489-044E0636-11CA-4D4C-B70A-5CAA5E74CC64Q53669221-EB5B6291-D8D4-4E4E-8779-6C60E0EB60BCQ54978311-B2AF3A73-9B57-4D18-833A-DFB0F6C87B27Q59220860-BB47F3C5-718B-489D-8482-DBE7F48B30C2Q64947844-EF0D86A9-BE77-4284-86F3-D2E1B6F468A2Q82044929-54F0DB38-A2B0-42C9-8987-2F7E6FABECAFQ89018228-0900BC1D-D952-4140-95B8-134F4731C139Q89790527-20A13915-6167-4900-B9C0-1B3E11C38C68Q90030010-2B26A4B6-6043-4EE9-AA39-16F410A0FFC7Q90430590-1498A55F-5915-4A54-9663-82C1B26ADBAEQ91104724-3E825C9D-6842-4CCE-BFA1-1B6B578BBFA8Q91259737-7B376212-B579-46E0-B142-C471FBCD7BB9Q91586214-EB2C644B-6BC7-48A5-A4BE-5BBF66A16055Q92289751-53E0B7CA-7A54-4D42-BEC8-400E7D611276Q92409975-01913CF1-44BB-48B7-9720-8757FB77844CQ92451925-1E513B0C-CAD8-475A-AE44-CAB468E18700Q92724375-43762FEF-C7E1-4882-952B-F53B5A6380B1
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Elisabetta Marangoni
@en
Elisabetta Marangoni
@nl
type
label
Elisabetta Marangoni
@en
Elisabetta Marangoni
@nl
prefLabel
Elisabetta Marangoni
@en
Elisabetta Marangoni
@nl
P31
P496
0000-0002-3337-6448